Cholestech's Consumer Play
Cholestech Inc. a maker of point-of-care diagnostic tests for cholesterol levels, is revamping its strategy to focus more on the consumer. It is buying Health Net, a small operator of alternative site testing services, such as those offered in corporations, shopping malls and at special events, to help augment relationships with pharmaceutical companies and to expand its Internet presence. Calling its new services WellCheck, it aims to attract pharmaceutical companies to sponsor consumer testing programs. Health Net has about $3 million in revenues, much of it coming from Warner-Lambert's Parke Davis subsidiary and Pfizer Inc., which have a co-marketing agreement to sell Lipitor, the best-selling cholesterol-lowering drug. The drug companies are supporting Health Net's testing efforts in the hopes of increasing awareness of their drug and perhaps more importantly improving compliance. Cholestech is also setting up its own Internet portal via WellCheck. Inc., which will be sponsored by pharmaceutical companies and which will allow consumers to maintain their health records on line.
You may also be interested in...
New data seems to indicate an uptick in the percentage of premarket applications that receive a major deficiency letter. See what US FDA spokesperson Alison Hunt said about strategies to avoid them.
Japanese firm says it will end SHP647 development after trying unsuccessfully to find takers for GI drug similar to its blockbuster Entyvio, first flagged by European authorities over competition worries.
The Environmental Working Group and US PIRG suggest that beauty and personal-care firms should avoid using talc in loose powders, if not all cosmetic products, and that the US FDA should consider banning the ingredient due to the potential for asbestos contamination, among other concerns.